Pharmafile Logo

Article: The Patient Abroad

April 2, 2015 |  

Published in Medical Marketing & Media March 2015

Approximately 11 million people were medical tourists in 2013, generating a market worth over $50 billion. While obtaining accurate data is challenging, estimates suggest the global medical tourism market is expanding by 25% each year.

Having grown up in the UK, where high-quality healthcare is available to all through the National Health Service, I hadn’t given the concept of medical tourism a great deal of thought before I moved to Asia. It would simply not have occurred to me to seek healthcare overseas for any other reason than if I happened to fall ill while traveling. 

I first became aware of the concept when reading rumors that Zimbabwe’s President Robert Mugabe was being treated in one of Singapore’s exclusive private hospitals – which happened to be just down the road from my apartment at the time. This led to much discussion among my peers about how much it would cost to be a medical tourist in Singapore. “High end” patients can expect to accrue bills of thousands of dollars. The most expensive “hospitel” (hospital hotel) penthouse suite (not room) in Singapore costs over $8,000 per night – and it does not include the additional costs of medical treatment. This particular establishment anticipates that at least half of its “guests” (not patients) will come from overseas.

Read the full article on Medical Marketing & Media »

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

AAD conference 2016

Therapy Watch recently presented “real-world” patient data on treatment duration and persistence among European PsO patients

Video: Global Biosimilars Market

Research director of Therapy Watch, Laurent Chanroux, discusses the growth opportunities for biosimilars and the importance of adaptable market tracking for pre and post product launch

Case study: Understanding Patient Willingness to Pay in Emerging Markets

Our client wanted to identify the optimum selling price for their chronic disease treatment in emerging markets, based on patient’s willingness to pay for the product out of pocket.Find out...

From promise to practice: immuno-oncology in action Part 3 – Emerging Markets

Our latest white paper on immuno-oncology explores the challenges and opportunities in emerging markets, with a focus on Asia.

It’s a digital hat trick for Pegasus as it scoops GOLD and two SILVERS at the PM Society Digital Awards 2016

Pegasus received three top accolades at the PM Society Digital Media Awards 2016, including gold for the highly acclaimed Craft: Best Innovation award with Biogen’s MS Explorer, and two silvers...

What we do and who we do it for | Pegasus

We’ve built a new type of health communications consultancy. One that believes in a ‘health first, sector second’ approach. One that connects with every stakeholder. One that blends traditional, digital...

Understanding decision making in health | Pegasus

To reflect the importance of self-care in health, we developed and launched a new model for exploring personal health decision-making which provides a framework for strategic planning, whatever the therapy...

An animated approach to communicating healthy messages | Pegasus

Telling a health message is one half of the battle. Ensuring that these messages resonate is another matter entirely. The Lab is our 25-strong, in-house creative and content team within...

Pegasus shortlisted for four PM Society Digital Media Awards 2016

Pegasus, the UK’s leading independent health communications consultancy, has had recognition of its work in digital media with shortlistings for four awards at the PM Society Digital Media Awards 2016...

Infographic: HCV EU

Research findings from our Therapy HCV study shows that 28% of HCV patients in the EU are infected by sharing needles or drug equipment.Our latest market snapshot offers an introduction...